CARLSBAD, Calif. — Thermo Fisher Scientific and pharmaceutical companies GlaxoSmithKline and Pfizer have entered into an agreement to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as a companion diagnostic for multiple drug programs. Thermo Fisher intends to submit this test for premarket approval to the Food and Drug […]

Cambridge, UK — Horizon Discovery Group plc (LSE: HZD) (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announces that its business unit Horizon Diagnostics has signed a Master Services Agreement with a major global diagnostic development company and a US biopharmaceutical company to support the […]

Budapest, Hungary; Cambridge, MA & Richmond, VA — Global biotechnology company Omixon, headquartered in Budapest with US offices in Cambridge, MA, has announced a collaboration with Global Genomics Group (G3) to validate its Target HLA™ software to determine HLA genotypes from whole genome sequencing (WGS) datasets. G3 is providing the WGS datasets and the corresponding […]

Vienna/Brno/Berlin — Colon cancer is one of the most common cancers being the second most common cause of cancer in women and the third most common in men. At the same time colon cancer is the fourth common cause of cancer related death. Early detection of this disease increases both the therapeutic success and the […]

DELRAY BEACH, Fla.– PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that it is accelerating the prototype development of its Firefly Dx system, a handheld, real-time PCR (polymerase chain reaction) system designed to provide molecular diagnostic results in less than 20 minutes at the point of need. […]

CARLSBAD, Calif. — Thermo Fisher Scientific today announced that it has completed the listing of its Ion PGM Dx next generation sequencing system with the U.S. Food and Drug Administration (FDA) for clinical use as a class II medical device. “Next generation sequencing is rapidly becoming an indispensable tool for clinical laboratories around the world, […]

BOSTON, MA and TUSCON, AZ — — Sunquest Information Systems and Partners HealthCare are establishing a strategic alliance to accelerate genomic-based medicine. The relationship involves a strategic investment by Sunquest into GeneInsight, Inc., an IT platform company that streamlines the analysis, interpretation, and reporting of complex genetic test results. Partners is a majority shareholder in […]

Woburn, MA — SeqLL Inc., the owner of the True Single Molecule Sequencing (tSMS™) technology, announced today the closing of a $1M Series-A funding round. This round of investment, led by Genomic Diagnostic Technologies, will increase the power of tSMS™ technology for scientific and diagnostic applications. Founded in March 2013 by Daniel Jones, a former […]

ALAMEDA, Calif. & JERUSALEM — BioTime, Inc. (NYSE MKT: BTX), HBL Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange: HDST) and Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has received the final results of a series of extensive preclinical safety and efficacy studies of its development-stage product designated OpRegen®, which is intended […]

ALAMEDA, Calif. & LONDON — OncoCyte Corporation, a subsidiary of BioTime, Inc. (NYSE MKT: BTX), and Abcodia Ltd., a UK-based company focusing on the early detection of cancer, today announced their collaboration focused on the development of OncoCyte’s blood-based PanC-Dx™ test for early detection of breast cancer. PanC-Dx™ is a class of non-invasive cancer diagnostics […]